Common use of New Presentations Clause in Contracts

New Presentations. The Conversion Charge for any New ----------------- Presentations shall be calculated as follows: [*] where (A) is the average per unit (e.g., tablet) Conversion Charge for those presentations of such Secondary/Steriles Product having the same dosage size as the New Presentation; (B) is the unit size of the New Presentation; [*] where (W) is the average per dosage unit (e.g., mg) Conversion Charge for those presentations of such Secondary/Steriles Product having the same package size as the New Presentation; (X) is the dosage size (in units) of the New Presentation; [*] = CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. [*] The Conversion Charge for each New Presentation shall be recalculated following the [*] the New Presentation is supplied under this Agreement (or until that New Presentation is no longer supplied, whichever first occurs), [*] by Supplier with respect to that New Presentation and the actual unit volumes of that New Presentation with Delivery Dates during the period. Incremental costs used in the recalculation shall include only the types of costs included in the initial calculation, and only increases or decreases therein shall be reflected in the recalculation. If the recalculated Conversion Charge exceeds the Conversion Charge calculated prior to the commencement of supply of any such New Presentation, GWI shall promptly pay to Supplier an amount equal to the excess times the number of units of that New Presentation with Delivery Dates in such period. If the recalculated Conversion Charge is less than the Conversion Charge calculated prior to the commencement of supply of any such New Presentation, Supplier shall credit to GWI an amount equal to the difference times the number of units of such New Presentation with Delivery Dates in such period on Supplier's next invoices for Products until fully recovered. The amount of any credits not applied against invoices to GWI as of the Termination Date shall be paid by Supplier to GWI within [*] the Termination Date.

Appears in 1 contract

Sources: Supply Agreement (Catalytica Inc)

New Presentations. The Conversion Charge for any New ----------------- Presentations shall be calculated as follows: [*] where (A) is the average per unit (e.g., tablet) Conversion Charge for those presentations of such Secondary/Steriles Product having the same dosage size as the New Presentation; (B) is the unit size of the New Presentation; [*] where (W) is the average per dosage unit (e.g., mg) Conversion Charge for those presentations of such Secondary/Steriles Product having the same package size as the New Presentation; (X) is the dosage size (in units) of the New Presentation; [*] [*] = CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. [*] The Conversion Charge for each New Presentation shall be recalculated following the [*] the New Presentation is supplied under this Agreement (or until that New Presentation is no longer supplied, whichever first occurs), [*] by Supplier with respect to that New Presentation and the actual unit volumes of that New Presentation with Delivery Dates during the period. Incremental costs used in the recalculation shall include only the types of costs included in the initial calculation, and only increases or decreases therein shall be reflected in the recalculation. If the recalculated Conversion Charge exceeds the Conversion Charge calculated prior to the commencement of supply of any such New Presentation, GWI shall promptly pay to Supplier an amount equal to the excess times the number of units of that New Presentation with Delivery Dates in such period. If the recalculated Conversion Charge is less than the Conversion Charge calculated prior to the commencement of supply of any such New Presentation, Supplier shall credit to GWI an amount equal to the difference times the number of units of such New Presentation with Delivery Dates in such period on Supplier's next invoices for Products until fully recovered. The amount of any credits not applied against invoices to GWI as of the Termination Date shall be paid by Supplier to GWI within [*] the Termination Date.

Appears in 1 contract

Sources: Supply Agreement (Catalytica Inc)

New Presentations. The Conversion Charge (a) During the Term, each Party (the “Developing Party”) shall notify the other Party of each New Presentation for any which it Controls the rights necessary for Commercialization in the other Party’s portion of the Territory and shall provide such factual information relating to the New ----------------- Presentations Presentation as is likely to be material to the other Party’s decision whether to Develop and Commercialize the New Presentation in accordance with this Agreement, including, at least, the items listed on Exhibit K. Each New Presentation notice shall describe the New Presentation with a level of detail that is comparable to the level of detail set forth in Exhibit G with respect to the Initial Licensed Products. In addition to the information set forth in Exhibit K, if the Developing Party considers the New Presentation to be a Combination Product, the Developing Party will inform the other Party of the applicable allocation formula set forth in Exhibit C proposed to be applied in calculating the Net Sales of such New Presentation and the invoice price(s), if known, or the [ * ], proposed to be applied in performing such calculation. If the Developing Party proposes to apply [ * ], rather than invoice prices, in the calculation of Net Sales pursuant to Exhibit C for such New Presentation and if the other Party disagrees with the [ * ] proposed by the Developing Party, the matter shall be calculated as follows: [*] where (A) is resolved [ * ]. If the average per unit (e.g.Developing Party, tablet) Conversion Charge for those presentations of such Secondary/Steriles Product having the same dosage size as in providing information pertaining to a New Presentation, does or does not characterize the New Presentation as a Combination Product and if the other Party disagrees, such matter (in addition to a determination of [ * ], if applicable) shall be resolved [ * ]. The determination [ * ] and shall apply whether such New Presentation becomes a Collaboration Product or a Declined Product; provided that if the allocation of Net Sales of a Combination Product is based on [ * ] and invoice prices become available, the invoice prices shall be used to allocate Net Sales in accordance with Exhibit C starting with the next calendar quarter. (b) The Developing Party may notify the other Party of a New Presentation under subparagraph (a) of this Section 4.1 at any time; provided that it does so no later than [ * ] before [ * ] for the New Presentation in the [ * ]. Within [ * ] after receipt of the Developing Party’s notice or, if later, final determination of status as a [ * ] and, if applicable, [ * ] pursuant to [ * ], the other Party may elect to Develop and Commercialize the New Presentation pursuant to this Agreement by providing the Developing Party with a written notice and paying fifty percent (50%) of the costs described in paragraph (c) of Exhibit K (an “Election”). A New Presentation for which a Party makes an Election shall be deemed a Collaboration Product. Following the designation of the first Collaboration Product under this Section 4.1, the Parties shall form a JSC pursuant to Section 5.1. If appropriate, the non-Developing Party’s Election shall include an agreement regarding one or more Third Party Agreements as contemplated by Section 2.4(a). For the sake of clarity, all of a Party’s Project Technology related to a New Presentation that becomes a Collaboration Product as provided herein and that was invented, discovered, developed or otherwise generated prior to the Election is included as part of the Developing Party’s Project Technology for purposes of this Agreement effective on the date on which the non-Developing Party makes an Election with respect to such New Presentation; . (Bc) is If a Developing Party does not Control the unit size rights necessary for Commercialization of a New Presentation in the other Party’s portion of the Territory, it shall, [ * ] for the New Presentation in the [ * ], notify the other Party of the New Presentation; [*] where (W) is the average per dosage unit (e.g., mg) Conversion Charge for those presentations of such Secondary/Steriles Product having the same package size as the New Presentation; (X) is the dosage size (in units) Presentation and provide a description of the New PresentationPresentation in a level of detail that is comparable to the level of detail set forth in Exhibit G with respect to the Initial Licensed Products, including the first three items listed in paragraph (a) on Exhibit K; [*] = CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. [*] The Conversion Charge for each New Presentation provided that, if Bayer is the Developing Party, the Parties shall be recalculated following the [*] agree whether or not the New Presentation is supplied under this Agreement (or until that New Presentation a Combination Product and, if it is no longer supplieda Combination Product, whichever first occurs)the applicable allocation formula, [*] by Supplier with respect to that New Presentation and including, if required, the actual unit volumes of that New Presentation with Delivery Dates during the period. Incremental costs used in the recalculation shall include only the types of costs included in the initial calculation, and only increases or decreases therein shall be reflected in the recalculation. If the recalculated Conversion Charge exceeds the Conversion Charge calculated prior to the commencement of supply of any such New Presentation, GWI shall promptly pay to Supplier an amount equal to the excess times the number of units of that New Presentation with Delivery Dates in such period. If the recalculated Conversion Charge is less than the Conversion Charge calculated prior to the commencement of supply of any such New Presentation, Supplier shall credit to GWI an amount equal to the difference times the number of units of such New Presentation with Delivery Dates in such period on Supplier's next invoices for Products until fully recovered. The amount of any credits not applied against invoices to GWI as fair market value of the Termination Date shall be paid by Supplier to GWI within [*] components in accordance with the Termination Dateprocedure set forth in Section 4.1(a).

Appears in 1 contract

Sources: License and Collaboration Agreement (Zymogenetics Inc)